From Lab To Launch - Faster

Accelerated timelines are increasingly critical for biopharma programs, particularly when therapies address high unmet or orphan indications. Moving from late-stage development into commercial readiness, however, requires more than speed alone—it demands robust control strategies, cross-functional alignment, and disciplined execution to ensure regulatory confidence. See how an accelerated process performance qualification (PPQ) strategy enabled rapid progression from technology transfer to successful completion of three PPQ runs within a compressed timeframe. Faced with a potent molecule expressed in E. coli, the program required simultaneous analytical validation, extensive process characterization, and reconfiguration of manufacturing operations, including the integration of bespoke and single-use downstream equipment.

Thoughtful collaboration, flexible manufacturing strategies, and early risk mitigation can shorten the path from lab to launch without compromising quality or readiness for submission.